Baxter International’s stock price has stabilized after a 22% decline, with analysts remaining optimistic about the company’s prospects and predicting a potential 43% upside.
Baxter International has launched its revolutionary Hemopatch Sealing Hemostat in Europe, a breakthrough innovation that empowers surgeons to control bleeding and prevent leakage with unprecedented precision.
Baxter International has launched its revolutionary Hemopatch Sealing Hemostat in Europe, a breakthrough product that empowers surgeons to control bleeding and prevent leakage with unprecedented precision.
Baxter International’s stock value has surged, outperforming the healthcare sector, driven by strong Q4 results and the success of its innovative medical device, the Novum IQ pump.